Evidence map›Paper›PMID 33235942›Full record

ArticleInfectious Disease Modelling2021

Modelling the test, trace and quarantine strategy to control the COVID-19 epidemic in the state of São Paulo, Brazil.

Marcos Amaku, Dimas Tadeu Covas, Francisco Antonio Bezerra Coutinho, Raymundo Soares Azevedo Neto, Claudio Struchiner, Annelies Wilder-Smith, Eduardo Massad

Abstract read
In one paragraph

Article in Infectious Disease Modelling, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Marcos AmakuSchool of Medicine, University of Sao Paulo and LIM01-HCFMUSP, Sao Paulo, Brazil.
Dimas Tadeu CovasInstituto Butantan, Sao Paulo, Brazil.
Francisco Antonio Bezerra CoutinhoSchool of Medicine, University of Sao Paulo and LIM01-HCFMUSP, Sao Paulo, Brazil.
Raymundo Soares Azevedo NetoSchool of Medicine, University of Sao Paulo and LIM01-HCFMUSP, Sao Paulo, Brazil.
Claudio StruchinerSchool of Applied Mathematics, Fundacao Getulio Vargas, Rio de Janeiro, Brazil.
Annelies Wilder-SmithDepartment Public Health and Clinical, Heidelberg Institute of Global Health, University of Heidelberg, Germany.
Eduardo MassadSchool of Medicine, University of Sao Paulo and LIM01-HCFMUSP, Sao Paulo, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Testing for detecting the infection by SARS-CoV-2 is the bridge between the lockdown and the opening of society. In this paper we modelled and simulated a test-trace-and-quarantine strategy to control the COVID-19 outbreak in the State of São Paulo, Brasil. The State of São Paulo failed to adopt an effective social distancing strategy, reaching at most 59% in late March and started to relax the measures in late June, dropping to 41% in 08 August. Therefore, São Paulo relies heavily on a massive testing strategy in the attempt to control the epidemic. Two alternative strategies combined with economic evaluations were simulated. One strategy included indiscriminately testing the entire population of the State, reaching more than 40 million people at a maximum cost of 2.25 billion USD, that would reduce the total number of cases by the end of 2020 by 90%. The second strategy investigated testing only symptomatic cases and their immediate contacts - this strategy reached a maximum cost of 150 million USD but also reduced the number of cases by 90%. The conclusion is that if the State of São Paulo had decided to adopt the simulated strategy on April the 1st, it would have been possible to reduce the total number of cases by 90% at a cost of 2.25 billion US dollars for the indiscriminate strategy but at a much smaller cost of 125 million US dollars for the selective testing of symptomatic cases and their contacts.

Indexed as

Cost-analysisCOVID-19ModellingSARS-CoV-2Testing

Identifiers

PMID33235942
PMCPMC7677040

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.